These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 12557697)
1. [The new mechanisms and reversal of drug resistance]. Akiyama S Gan To Kagaku Ryoho; 2003 Jan; 30(1):1-8. PubMed ID: 12557697 [TBL] [Abstract][Full Text] [Related]
2. [Genetic alterations and chemoresistance]. Akiyama S Gan To Kagaku Ryoho; 2005 Nov; 32(12):1895-901. PubMed ID: 16282723 [TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153 [TBL] [Abstract][Full Text] [Related]
5. Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib. Glodkowska-Mrowka E; Mrowka P; Basak GW; Niesiobedzka-Krezel J; Seferynska I; Wlodarski PK; Jakobisiak M; Stoklosa T Exp Hematol; 2014 Jun; 42(6):439-47. PubMed ID: 24667683 [TBL] [Abstract][Full Text] [Related]
6. Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. Shukla S; Sauna ZE; Ambudkar SV Leukemia; 2008 Feb; 22(2):445-7. PubMed ID: 17690695 [No Abstract] [Full Text] [Related]
7. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib. Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016 [TBL] [Abstract][Full Text] [Related]
8. Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma. Chu TS; Chen JS; Lopez JP; Pardo FS; Aguilera J; Ongkeko WM Arch Otolaryngol Head Neck Surg; 2008 Sep; 134(9):979-84. PubMed ID: 18794444 [TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib. Théou N; Gil S; Devocelle A; Julié C; Lavergne-Slove A; Beauchet A; Callard P; Farinotti R; Le Cesne A; Lemoine A; Faivre-Bonhomme L; Emile JF Clin Cancer Res; 2005 Nov; 11(21):7593-8. PubMed ID: 16278376 [TBL] [Abstract][Full Text] [Related]
10. ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells. Declèves X; Bihorel S; Debray M; Yousif S; Camenisch G; Scherrmann JM Pharmacol Res; 2008 Mar; 57(3):214-22. PubMed ID: 18337118 [TBL] [Abstract][Full Text] [Related]
11. Celecoxib sensitizes imatinib-resistant K562 cells to imatinib by inhibiting MRP1-5, ABCA2 and ABCG2 transporters via Wnt and Ras signaling pathways. Dharmapuri G; Doneti R; Philip GH; Kalle AM Leuk Res; 2015 Jul; 39(7):696-701. PubMed ID: 25916699 [TBL] [Abstract][Full Text] [Related]
13. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Turrini E; Haenisch S; Laechelt S; Diewock T; Bruhn O; Cascorbi I Pharmacogenet Genomics; 2012 Mar; 22(3):198-205. PubMed ID: 22241070 [TBL] [Abstract][Full Text] [Related]
14. Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug Resistance. Li S; Zhang W; Yin X; Xing S; Xie HQ; Cao Z; Zhao B Anticancer Agents Med Chem; 2015; 15(4):423-32. PubMed ID: 25929575 [TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of ATP-binding cassette transporters and clinical implications. Cascorbi I; Haenisch S Methods Mol Biol; 2010; 596():95-121. PubMed ID: 19949922 [TBL] [Abstract][Full Text] [Related]
16. [Resistance mechanism of ST1571 and its prevention research--review]. Zhou X; Hou J Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Oct; 12(5):713-7. PubMed ID: 15498142 [TBL] [Abstract][Full Text] [Related]
17. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Wang L; Giannoudis A; Lane S; Williamson P; Pirmohamed M; Clark RE Clin Pharmacol Ther; 2008 Feb; 83(2):258-64. PubMed ID: 17568400 [TBL] [Abstract][Full Text] [Related]
18. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847 [TBL] [Abstract][Full Text] [Related]
19. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Hiwase DK; Saunders V; Hewett D; Frede A; Zrim S; Dang P; Eadie L; To LB; Melo J; Kumar S; Hughes TP; White DL Clin Cancer Res; 2008 Jun; 14(12):3881-8. PubMed ID: 18559609 [TBL] [Abstract][Full Text] [Related]